X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with PLETHICO PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs PLETHICO PHARMA - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA PLETHICO PHARMA CIPLA/
PLETHICO PHARMA
 
P/E (TTM) x 39.2 -1.1 - View Chart
P/BV x 3.4 0.0 20,033.3% View Chart
Dividend Yield % 0.4 0.0 -  

Financials

 CIPLA   PLETHICO PHARMA
EQUITY SHARE DATA
    CIPLA
Mar-17
PLETHICO PHARMA
Mar-14
CIPLA/
PLETHICO PHARMA
5-Yr Chart
Click to enlarge
High Rs622395 157.5%   
Low Rs45831 1,464.2%   
Sales per share (Unadj.) Rs181.9604.4 30.1%  
Earnings per share (Unadj.) Rs12.932.5 39.6%  
Cash flow per share (Unadj.) Rs29.351.3 57.1%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs155.7473.6 32.9%  
Shares outstanding (eoy) m804.5134.08 2,360.7%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.00.4 842.4%   
Avg P/E ratio x42.06.6 639.6%  
P/CF ratio (eoy) x18.44.2 443.8%  
Price / Book Value ratio x3.50.5 770.9%  
Dividend payout %15.50-   
Avg Mkt Cap Rs m434,5167,262 5,983.0%   
No. of employees `00023.0NA-   
Total wages/salary Rs m26,3381,596 1,650.3%   
Avg. sales/employee Rs Th6,349.1NM-  
Avg. wages/employee Rs Th1,143.0NM-  
Avg. net profit/employee Rs Th449.3NM-  
INCOME DATA
Net Sales Rs m146,30220,598 710.3%  
Other income Rs m2,287386 591.9%   
Total revenues Rs m148,58920,984 708.1%   
Gross profit Rs m24,7582,818 878.7%  
Depreciation Rs m13,229642 2,059.7%   
Interest Rs m1,5941,593 100.0%   
Profit before tax Rs m12,222969 1,261.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m-700-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,798-138 -1,299.0%   
Profit after tax Rs m10,3541,107 935.4%  
Gross profit margin %16.913.7 123.7%  
Effective tax rate %14.7-14.3 -102.9%   
Net profit margin %7.15.4 131.7%  
BALANCE SHEET DATA
Current assets Rs m87,37018,877 462.8%   
Current liabilities Rs m33,08111,896 278.1%   
Net working cap to sales %37.133.9 109.5%  
Current ratio x2.61.6 166.4%  
Inventory Days Days8736 242.0%  
Debtors Days Days62198 31.5%  
Net fixed assets Rs m111,5679,861 1,131.5%   
Share capital Rs m1,609341 472.3%   
"Free" reserves Rs m123,64512,331 1,002.8%   
Net worth Rs m125,25416,139 776.1%   
Long term debt Rs m36,4544,706 774.7%   
Total assets Rs m209,53233,146 632.2%  
Interest coverage x8.71.6 539.1%   
Debt to equity ratio x0.30.3 99.8%  
Sales to assets ratio x0.70.6 112.4%   
Return on assets %5.78.1 70.0%  
Return on equity %8.36.9 120.5%  
Return on capital %8.512.3 69.2%  
Exports to sales %34.221.4 160.1%   
Imports to sales %8.315.2 54.8%   
Exports (fob) Rs m50,0504,402 1,136.9%   
Imports (cif) Rs m12,2033,136 389.1%   
Fx inflow Rs m51,0664,402 1,160.0%   
Fx outflow Rs m17,6783,184 555.2%   
Net fx Rs m33,3881,219 2,740.1%   
CASH FLOW
From Operations Rs m23,8242,437 977.4%  
From Investments Rs m-13,127-6,265 209.5%  
From Financial Activity Rs m-13,2392,490 -531.6%  
Net Cashflow Rs m-2,478-1,337 185.3%  

Share Holding

Indian Promoters % 16.0 82.7 19.3%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 4.3 283.7%  
FIIs % 23.7 5.5 430.9%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 7.5 349.3%  
Shareholders   161,166 10,665 1,511.2%  
Pledged promoter(s) holding % 0.0 85.7 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   PFIZER  ABBOTT INDIA  PANACEA BIOTECH  DR. REDDYS LAB  GSK PHARMA  

Compare CIPLA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Trade on a Negative Note; Sensex Down Over 160 Points(12:30 pm)

After opening the day marginally higher, share markets in India witnessed selling pressure and are presently trading on a negative note.

Related Views on News

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top Five Stocks After the Karnataka Elections(The 5 Minute Wrapup)

May 16, 2018

The markets seem confused. They're neither going up nor down. What should investors do? Consider Safe Stocks. Here's the top 5 Safe Stocks in the market today.

How A Storm Destroyed Rain Industries... And a Superb Small Cap Stock I Recommend(Profit Hunter)

May 17, 2018

A mutual fund regulation could cause small cap prices to tank - If you haven't been paying attention to your small caps - now is the time to catch the opportunities that start pouring in.

Has the Indian Home Buyer Become Smarter?(Vivek Kaul's Diary)

May 17, 2018

Home loans continue to grow, despite falling sales. What explains this phenomenon?

Looking Beyond the Colourful Prism of This Airline Company(Sector Info)

May 10, 2018

Can Interglobe Aviation Safely Fly Out of Turbulence?

HDFC Prudence Fund Now HDFC Balanced Advantage Fund - Time To Sell?(Outside View)

May 9, 2018

PersonalFN provides detail analysis on HDFC Balanced Advantage Fund (erstwhile HDFC Prudence Fund and HDFC Growth Fund).

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


May 21, 2018 02:03 PM

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS